EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy



Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy



Experimental Neurology 271: 36-45



An inherited deficiency of β-galactosylceramidase (GALC) causes the lysosomal storage disease globoid cell leukodystrophy (GLD). The disease is characterized by the accumulation of the cytotoxic metabolite psychosine (galactosylsphingosine), causing rapid degeneration of myelinating cells. Most patients suffer from the infantile form of GLD with onset of disease between 3 and 6 months after birth and death by 2 years of age. The most widely used animal model of GLD, the twitcher mouse, presents with an even more rapid course of disease and death around 40 days of age. We have generated a novel "humanized" mouse model of GLD by inserting a human GALC cDNA containing an adult-onset patient mutation into the murine GALC gene. Humanized GALC mice exhibit pathological hallmarks of GLD including psychosine accumulation, neuroinflammation, CNS infiltration of macrophages, astrogliosis and demyelination. Residual GALC activities in mouse tissues are low and the mice display a median lifespan of 46 days. Due to the expression of the human transgene, the mice do not develop an immune response against rhGALC, rendering the animal model suitable for therapies based on human enzyme. Intravenously injected rhGALC was able to surmount the blood-brain barrier and was targeted to lysosomes of brain macrophages, astrocytes and neurons. High-dose enzyme replacement therapy started at postnatal day 21 reduced the elevated psychosine levels in the peripheral and central nervous system by 14-16%, but did not ameliorate neuroinflammation, demyelination and lifespan. These results may indicate that treatment must be started earlier before pathology occurs.

(PDF emailed within 0-6 h: $19.90)

Accession: 057778544

Download citation: RISBibTeXText

PMID: 25956830

DOI: 10.1016/j.expneurol.2015.04.020



Related references

Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy. Faseb Journal 19(11): 1549-1551, 2005

Enzyme replacement therapy for globoid cell leukodystrophy. 2008

Bone marrow transplantation increases efficacy of central nervous system-directed enzyme replacement therapy in the murine model of globoid cell leukodystrophy. Molecular Genetics and Metabolism 107(1-2): 186-196, 2013

Globoid cell leukodystrophy: enzymatic diagnosis in two families, and enzyme replacement therapy. No to Shinkei 30(7): 727-733, 1978

Additional deficiency of psychosine galactosidase in globoid cell leukodystrophy: an implication to enzyme replacement therapy. Birth Defects Original Article Series 9(2): 136-140, 1973

Neural stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy. Stem Cells 29(10): 1559-1571, 2012

Enzyme replacement with liposomes in murine globoid cell leukodystrophy. American Journal of Human Genetics 41(3 SUPPL): A19, 1987

Therapeutic benefit of lentiviral-mediated neonatal intracerebral gene therapy in a mouse model of globoid cell leukodystrophy. Human Molecular Genetics 23(12): 3250-3268, 2015

Enzyme replacement with liposomes containing beta galactosidase from charonia lampas in murine globoid cell leukodystrophy twitcher. Biochemical & Biophysical Research Communications 127(2): 663-667, 1985

Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age. Human Molecular Genetics 21(11): 2599-2609, 2012

The twitcher mouse A model of human globoid cell leukodystrophy. Martenson, R E Myelin: Biology and chemistry ix+958p CRC Press, Inc : Boca Raton, Florida, USA; London, England, UK Illus ISBN 0-8493-8849-X : 745-759, 1992

Globoid cell leukodystrophy: specialized contact of globoid cell with astrocyte in the brain of twitcher mouse. Acta Neuropathologica 58(4): 237-242, 1982

Macrophages counteract demyelination in a mouse model of globoid cell leukodystrophy. Journal of Neuroscience 31(10): 3610-3624, 2011

The twitcher mouse. A model of human globoid cell leukodystrophy (krabbe's disease). American Journal of Pathology 111(3): 394-397, 1983